UBS Reiterates Buy Rating on DaVita (DVA)

UBS analyst AJ Rice reiterated a Buy rating and $186.00 price target on DaVita (NYSE: DVA).

The analyst commented, "DVA continues to expect long run adj. operating income growth in the 3-7% range, but has not given specific guidance for 2026. The building blocks for 3-7% adj. operating income (OI) growth haven't changed, with management noting that in a typical year the company could see 2% OI growth from U.S. dialysis, 1% from IKC, and another 1% from international. The 2% U.S. dialysis number assumes stable margins and solid RPT growth, but could be higher if volume growth returns. DVA continues to expect to reach breakeven in the IKC (Integrated Kidney Care) segment in 2026."

For an analyst ratings summary and ratings history on DaVita click here. For more ratings news on DaVita click here.

Shares of DaVita closed at $121.35 yesterday.

You May Also Be Interested In

• Lake Street Starts RF Industries Ltd. (RFIL) at Buy
• DuPont's lithium extraction team wins 2026 sustainability award
• Ackman adds Netflix, Visa and Mastercard in portfolio revamp